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Background: This study evaluated whether clinical and economic outcomes from CBT for child anxiety disorders in
the context of maternal anxiety disorders are improved by adding treatment focused on (a) maternal anxiety disorders
or (b) mother–child interactions. Methods: Two hundred and eleven children (7–12 years, 85% White British, 52%
female) with a primary anxiety disorder, whose mothers also had a current anxiety disorder, were randomised to
receive (a) child-focused CBT with nonspecific control interventions (CCBT+Con), (b) CCBT with CBT for the maternal
anxiety disorder (CCBT+MCBT), or (c) CCBT with an intervention targeting the mother–child interaction (CCBT+MCI).
A cost-utility analysis from a societal perspective was conducted using mother/child combined quality-adjusted life
years (QALYs). [Trial registration: https://doi.org/10.1186/isrctn19762288]. Results: MCBT was associated with
immediate reductions in maternal anxiety compared to the nonspecific control; however, after children had also
received CCBT, maternal outcomes in the CCBT+MCI and CCBT+Con arms improved and CCBT+MCBT was no longer
superior. Neither CCBT+MCBT nor CCBT+MCI conferred a benefit over CCBT+Con in terms of child anxiety disorder
diagnoses post-treatment [primary outcome] (adj RR: 1.22 (95% CI: 0.88, 1.67), p = .23; adj RR: 1.21 (95% CI: 0.88,
1.65), p = .24, respectively) or global improvement ratings (adj RR: 1.25 (95% CI: 0.99, 1.57), p = .06; adj RR: 1.18
(95% CI: 0.93, 1.50), p = .17) or six and 12 months later. No significant differences between the groups were found on
the main economic outcome measures (child/mother combined QALY mean difference: CCBT+MCBT vs. CCBT+Con:
0.04 (95% CI: 0.12, 0.04), p = .29; CCBT+MCI vs. CCBT+Con: 0.02 (95% CI: 0.05, 0.09), p = .54). CCBT+MCI
was associated with nonsignificantly higher costs than CCBT (mean difference: £154 (95% CI: £1,239, £1,547),
p = .83) but, when taking into account sampling uncertainty, it may be cost-effective compared with CCBT alone.
Conclusions: Good outcomes were achieved for children and their mothers across treatment arms. There was no
evidence of significant clinical benefit from supplementing CCBT with either CBT for the maternal anxiety disorder or
treatment focussed on mother–child interactions, but the addition of MCI (and not MCBT) may be cost-effective.
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Introduction
Anxiety disorders are among the most common
psychological disorders in childhood affecting 2.6%–
5.2% of children under the age of 12 years (e.g.
Costello, Egger, & Angold, 2004). They negatively
affect children’s functioning (Essau, Conradt, &
Petermann, 2000), raise the risk for disorders in
adolescence and adulthood (Woodward & Fergusson,
2001), and carry a substantial health and social cost
(Bodden, Dirksen, & Bogels, 2008). There is consid-
erable evidence for the efficacy of cognitive behaviour
therapy (CBT) for these disorders, with 59% of anx-
ious children no longer meeting criteria for an anxiety
disorder following CBT (James, James, Cowdrey,
Soler, & Choke, 2013). However, where a parent has
an anxiety disorder, rates of child recovery have been
found to be as little as half compared to when there is
no parental anxiety disorder (Bodden, B€ogels et al.,
2008; Hudson et al., 2014). Two studies to date have
examined whether specifically targeting elevated
parental anxiety might benefit child treatment out-
come (with treatments delivered in group formats).
One of these studies reported a positive impact on
anxious children of parents with high trait anxiety
(Cobham, Dadds, & Spence, 1998), at least in the
short term, while the other reported no benefit for
anxious children of parents with a current anxiety
disorder (Hudson et al., 2014). Notably, both of these
studies administered relatively brief treatments for
parental anxiety (4 and 3.75 hr, respectively) and
neither brought about significant reductions in*Joint first authors.
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parental anxiety. The question therefore remains
open whether successful treatment of parental anx-
iety might benefit child outcome.
It is possible that targeting parent–child interac-
tions that are likely to interfere with the child’s
treatment – that is reducing parent cognitions and
behaviours that limit the child’s autonomy and
promote the child’s focus on threat (Creswell, Mur-
ray, Stacey, & Cooper, 2011; Hudson & Rapee, 2004)
– may be of benefit for anxious children in the
context of parental anxiety disorder (Settipani,
O’Neil, Podell, Beidas, & Kendall, 2013). Indeed,
parental cognitions characterised by expectations
that the child will be frightened and feel out of
control in the face of a challenge and behaviours
characterised by intrusiveness and modelling of fear
have been found to occur more commonly in anxious
compared to nonanxious parents of children with
anxiety disorders (Creswell, Apetroaia, Murray, &
Cooper, 2013; Moore, Whaley, & Sigman, 2004).
In view of the roles of parental anxiety as well as
parenting cognitions and behaviour in maintaining
child anxiety, the current study tested the hypoth-
esis that clinical outcomes for child anxiety disor-
ders presenting in the context of parental anxiety
disorders will be improved by supplementing indi-
vidual child CBT with (a) treatment of parental
anxiety disorders or (b) treatment focused on par-
ent–child interactions.
This study also evaluated whether supplementing
CBT with these adjunct treatments represents good
value for money. The few published cost-effective-
ness analyses of the treatment of child anxiety
mainly concern the value of child CBT compared
with a wider family approach (Bodden, B€ogels et al.,
2008; Bodden, Dirksen, & Bogels, 2008) or with a
parent-directed treatment for child anxiety (Simon,
Dirksen, B€ogels, & Bodden, 2012). There is, how-
ever, a paucity of evidence on the short-term and
long-term cost-effectiveness of alternative configura-
tions of treatment types involving maternal and child
treatment combinations, which are likely to be of
particular relevance when maternal anxiety disorder
is present. Furthermore, no economic evaluations of
the treatment of child anxiety have taken into
account both the direct effects to the child and
‘spillover’ effects, for example, to the parents and
wider society. For outcomes, this is achieved by
using quality-adjusted life years (QALY), a generic
measure of outcome that can be aggregated across
individuals (Weinstein, Torrance, & McGuire, 2009)
and allows for examination of both direct treatment
and spillover effects (Tilford et al., 2015). For costs,
this is achieved by measuring broader impacts on
education and employment. Aggregating direct and
spillover effects may alter cost-effectiveness profiles,
a particularly appropriate strategy when the eco-
nomic evaluation adopts a societal perspective.
Indeed, recommendations from a recent review of
family-based therapies suggest that future research
in this field should include such spillover effects to
the rest of the family as well as consider cost and
effectiveness over a longer time horizon (Tubeuf &
Guthmuller, 2017). Further, few evaluations to date
have formally aggregated QALYs as a means of
capturing spillover effects. The current study there-
fore tested the value for money of the two supple-
mentary interventions, considering spillover effects,
societal impacts and including a one-year follow-up.
Methods
Participants
Participants comprised 211 children, aged 7–12 years (mean
age = 10.22, SD = 1.58), with a current anxiety disorder,
together with their mothers, who also had a current anxiety
disorder. The study was powered to provide 90% power at the
5% (two-sided) significance level to detect a 30% difference in
the primary outcome – that is the proportion of children who
recovered from their primary anxiety disorder at the post-
treatment assessment in the CCBT+MCI or CCBT+MCBT arms
compared to the CCBT+Con arm. The estimated remission rate
for the CCBT+Con group was 40% (based on Cobham et al.,
1998). A difference of 30% in the proportion of anxiety-free
children following completion of the treatment was considered
to be the minimum that would be clinically worthwhile taking
into account the increased resources required and change to
service delivery that would be required if either of these
interventions was found to be effective and implemented in
practice. The sample size was defined on the basis of two
independent trials as recommended by Machin, Campbell,
Fayers, and Pinol (1997). The required sample size of 56
children per group was increased to allow for an estimated 20%
loss to follow-up.
The study focussed on mothers as (a) intergenerational
associations for anxiety disorders are most commonly found
between mothers and their children (Cooper, Fearn, Willetts,
Seabrook, & Parkinson, 2006), (b) mothers are most commonly
the primary caregivers in the study region, and (c) maternal
and paternal behaviours may differ in how they are associated
with childhood anxiety (B€ogels & Perotti, 2011).
Participants were recruited between June 2008 and May
2011, with the last follow-up assessment in February 2013.
Participating children were all referred to a university research
clinic for treatment by a health or educational professional. The
inclusion criteria were (a) the child must (i) be aged 7–12 years;
(ii) have a current primary diagnosis of a DSM-IV anxiety
disorder (if specific phobia, this must be comorbid with another
anxiety disorder); and (b) the child’s mother must (i) be the
primary carer; and (ii)meet criteria for a currentDSM-IV anxiety
disorder. The exclusion criteria were (i) significant physical or
intellectual impairment (including autistic spectrum disorders)
in the child or mother; (ii) current prescription of psychotropic
medication for the child or mother that had not been at a stable
dose for at least one month and without agreement to maintain
that dose throughout the study; and (iii) the childhadpreviously
received six or more sessions of CCBT for an anxiety disorder.
Participating children and mothers were given a complete
description of the study orally and in writing before giving
written informed assent/consent. A total of 676 children were
assessed for eligibility; 435 families did not meet the inclusion
criteria and 30 declined to participate (see Figure 1).
Procedure
The study was approved by the Berkshire Research Ethics
Committee (07/H0505/156) and the University of Reading
© 2019 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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Assessed for eligibility
(n = 676)
Randomised (n = 211)
CCBT+Con (n = 71) CCBT+MCBT (n = 69) CCBT+MCI (n = 71)
Assessment 1B 
(n = 64)
Assessment 1B
(n = 64 )
Assessment 1B 
(n = 70)
Not assessed (n = 7)
Reasons:
• Mother in other therapy (n = 1)
• Mother –did not attend (n = 5)
• Withdrew- Child improved 
  (n = 1)
Not assessed (n = 5)
Reasons:
• Mother did not attend 
   (n = 5)
Not assessed (n = 1)
Reasons:
• Withdrew  -Child improved 
  (n = 1)
Not assessed (n = 8)
Reasons:
• Did not attend (n = 5)
• Treatment complete but 
  declined assessment (n = 3)
Not assessed (n = 5)
Reasons:
• Did not attend (n = 1)
• Treatment complete but 
declined assessment 
(n = 4)
Not assessed (n = 8)*
Reasons:
• Did not attend (n = 5)
• Treatment complete but 
declined assessment 
(n = 2)*
• Exclude – Mother serious 
mental health concerns
(n = 1)
Total Excluded (n = 465)
Not meeting inclusion criteria (n = 435)
Reasons:
• Mother not anxious (n = 311)
• Mother other diagnosis (n = 7)
• Mother not primary care giver 
(n = 2)
• Child outside age range  (n = 3)
• Child Autistic Spectrum 
Disorder  (n = 8)
• Child Attention/Behavior 
Disorder Primary (n = 38)
• Child Mood Disorder Primary 
(n = 6)
• Child PTSD primary (n = 6)
• Child OCD Primary (n = 13)
• Child no Anxiety Disorder 
(n = 24)
• Child-other (n = 17)
• No consent to participate  
(n = 30)
Assessment 2  
(n = 56, 78.9% of 71) 
Assessment 2 
(n = 59, 85.5% 0f 69)
Assessment 2 
(n = 62, 87% of 71) 
PRIMARY OUTCOME
Assessment 3 
(n = 49) 69% 
Assessment 3
(n = 52) 75% 
Assessment 3
(n = 51) 72% 
Assessment 4 
(n = 43) 61% 
NB includes (n = 2) who
did not complete A3 
Assessment 4 
(n = 48) 70% 
NB includes (n = 3) who
did not complete A3 
Assessment 4 
(n = 46) 65% 
NB includes (n = 4) who
did not complete A3 
Not assessed (n = 11) 
Reasons: 
• Did not attend (n = 5) 
• Withdrew- left country 
(n = 2) 
• Declined A3 but 
completed A4 (n = 4) 
Not assessed (n =7) 
Reasons: 
• Did not attend (n = 4) 
• Declined A3 but 
completed A4 (n = 3) 
Not assessed (n =7)
Reasons: 
• Did not attend (n = 5) 
•  Declined A3 but 
completed A4 (n = 2) 
Not assessed (n = 8)
Reasons: 
• Did not attend (n = 7) 
• Lost contact (n = 1) 
Not assessed (n = 7)
Reasons: 
• Did not attend (n = 6) 
• Left country (n = 1) 
Not assessed (n = 9) 
Reasons: 
• Did not attend (n = 6) 
• Withdrew- lost contact 
(n = 3) 
CCBT+Con CCBT+MCBT CCBT+MCI 
Figure 1 Consort diagram. CCBT+Con, child-focused cognitive behaviour therapy + nonspecific control interventions; CCBT+MCBT, CCBT
+ CBT to target maternal anxiety disorder; CCBT+MCI, CCBT + intervention to target the mother–child interaction
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Research Ethics Committee (07/48). Participants were ran-
domised to one of three treatment arms: (a) child cognitive
behaviour therapy plus control interventions to balance for
therapist time (CCBT+Con) (see below); (b) CCBT plus cognitive
behaviour therapy for maternal anxiety disorder
(CCBT+MCBT); or (c) CCBT plus treatment focused on the
mother–child interaction (CCBT+MCI). Each of the three arms
included nonspecific therapeutic interventions to ensure treat-
ment arms were balanced for therapist contact with both
children and mothers (see Table 1).
Randomisation was performed externally at the Centre for
Statistics in Medicine (University of Oxford) on receipt of
anonymised participant information by fax. Patients were
randomised with a 1:1:1 ratio, with minimisation for child
age and gender, type of child anxiety disorder, and baseline
severity of both child and maternal primary anxiety disorder.
These minimisation variables were selected as they have been
most frequently (albeit not consistently) identified as predictors
of response to treatment for child anxiety disorders (Ginsburg
et al., 2011; Hudson et al., 2015). The minimisation algorithm
included a 20% random element.
Assessments of maternal anxiety disorder and parenting
were made before and immediately following the interven-
tions. Assessments of child anxiety disorder status and
severity were conducted before and following treatment, as
well as at six and 12 months following treatment. Different
research staff assessed the mother and the child.
Assessments of maternal and child health-related quality of
life were made on five occasions: before treatment (Assess-
ment 1), mid-way through treatment (1B), immediately
post-treatment (2), and at the six (3)- and 12-month (4)
follow-up. Data on the use of other health and social care
resources, as well as non-NHS cost-generating (e.g. educa-
tional) services and days off school or work, were obtained
from parent report. All assessors were blind to treatment
allocation. The trial was preregistered as follows https://doi.
org/10.1186/isrctn19762288. The protocol is provided in
Appendix S1.
Measures
Structured diagnostic interviews with children and
parents. Children were assigned diagnoses on the basis of
the Anxiety Disorders Interview Schedule for DSM-IV for Chil-
dren – Child and Parent Versions (ADIS-C/P; Silverman &
Albano, 1996). The presence or absence of a current maternal
anxiety disorder was assigned on the basis of the Anxiety
Disorders Interview Schedule for DSM-IV (ADIS-IV; DiNardo,
Barlow, & Brown, 1994). For the ADIS-C/P overall diagnoses
andclinical severity ratings (CSRs)wereassigned if the childmet
diagnostic criteria on the basis of either child or parent report.
Those with a CSR of 4 or more (at least moderate psychopathol-
ogy) were considered tomeet diagnostic criteria. Assessors were
thoroughly trained to ensure high levels of reliability (presence/
absence of child diagnosis j = .98 (child report), .98 (mother
report); CSR intraclass correlation = .99 (child report), .99
(mother report); presence/absence of maternal diagnosis
j = .97;CSR intraclass correlation = .99). Theprimaryoutcome
derived was absence of the child’s primary (most impairing)
anxiety disorder; secondary outcomes derived from the ADIS-c/
p were absence of all anxiety disorder diagnoses and CSR of the
primary anxiety disorder, as prespecified in the trial protocol
and statistical analysis plan (see Appendices S1 and S2).
Clinical Global Impressions: Improvement (CGI-
I). Overall improvement in child anxiety was assessed using
the Clinical Global Impression – Improvement scale (CGI-I), a
seven-point scale from 1 = very much improved to 7 = very
much worse; scores of 1 and 2 are accepted to represent
treatment success (Guy, 1976). Overall mean inter-rater reli-
ability for the assessment team was high (ICC = .96).
Symptoms of anxiety and comorbid difficulties were also
assessed as secondary outcomes using the Spence Child
Anxiety Scale (child, parent, teacher report), Child Anxiety
Impact Scale (child, parent report), Short Mood and Feelings
Questionnaire (child, parent report), conduct problems
Table 1 Overview of design
CCBT+MCBT CCBT+MCI CCBT+Con
Assessment 1
Pretreatment
Diagnostic assessment (mother and child) + laboratory observation of mother–child interaction
Treatment 1
(number of
sessions)
MCBT (8) NDC (2) NDC (8)
Assessment 1B
Mid-treatment
Diagnostic assessment (mother and child)
Treatment 2
(number of
sessions)
CCBT (8) + HLC (Mother:2; Child +
mother: 2)
CCBT (8) + MCI (Mother:8; Child
+ Mother: 2)
CCBT (8) + HLC (Mother:2; Child
+ mother: 2)
Assessment 2
Post-treatment
Diagnostic assessment (mother and child) + laboratory observation of mother–child interaction
Assessment 3
6 months
post-treatment
Diagnostic assessment (child)
Assessment 4
12 months
post-treatment
Diagnostic assessment (child)
Total therapy
sessions
Mother: 10
Child: 2
Child + Mother: 2
Mother: 10
Child: 2
Child + Mother: 2
Mother: 10
Child: 2
Child + Mother: 2
CCBT, child-focused cognitive behaviour therapy; CCBT-Con, child-focused cognitive behaviour therapy plus nonspecific control
interventions; MCBT, cognitive behaviour therapy targeting maternal anxiety diagnoses; NDC, nondirective counselling for mothers;
HLC, Healthy Living Control; MCI, mother–child interaction focussed treatment.
© 2019 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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subscale of the Strengths and Difficulties Questionnaire (child,
parent, teacher report) and a teacher report measure of Child
Adjustment to School. Descriptions of measures and outcomes
are provided in Table S1.
Assessment of parenting and parental expecta-
tions. In order to establish whether the intervention that
targeted mother–child interactions did successfully alter mater-
nal responses, we conducted laboratory observations under
conditions of mild social, performance and physical challenge
(Creswell et al., 2013). The social threat task involved the child
preparinganddeliveringaspeech,with theirmother’s support, to
a research assistant with a hand-held video camera. The perfor-
mance task involved the child attempting difficult tangram
puzzles (following the procedure of Hudson & Rapee, 2001). The
physical threat taskrequiredchildrento investigate thecontentof
four chambers within a mysterious ‘black box’. To account for
prior experience, the assessment was modified at the post-
treatment assessment point; in the social stress task, the child
was required to present to a panel rather than a single research
assistant, the tangrampuzzles weremore difficult, and the black
box was accompanied by sound effects (i.e. rustling/scratching).
Observers who were blind to treatment arm coded parental
behaviours on scales developed by Murray et al. (2012) and
adapted by Creswell et al. (2013) to be suitable for children
aged 7–12 years. Ratings were given for each minute of the
interaction on 5-point scales (1 = none, 5 = pervasive/strong).
Since interactions varied in duration, total scores across tasks
reflected the sum of the mean scores for each task. The
following behaviours were considered: maternal expressed
anxiety, overprotection, intrusiveness and positivity (warmth
and encouragement). For each coder, in each task, a second
coder independently scored a random sample of 25 videotapes.
Intraclass correlations showed acceptable agreement across all
indices (range .60–1.00; mean: .86).
Maternal expectations were assessed before initiating the
challenge tasks (Creswell et al., 2013). Immediately after
receiving the instructions for each task, mothers were taken
to a separate room and asked to provide ratings regarding (a)
how their child would feel about doing the task (0 = not scared
at all, 10 = extremely scared); and (b) how much their child
could do about how the task went (0 = nothing at all, 10 = a
lot). Ratings were combined across the three tasks to represent
their expectations across a range of challenge contexts.
Health-related quality of life. Mother and child health-
related quality of life (HRQoL) was measured using responses to
the EuroQol EQ-5D-3L (Dolan, Gudex, Kind, & Williams, 1995)
and EQ-5D-Youth version (Wille et al., 2010) instruments,
respectively. Responses for mother and child at each time point
were converted into utility weights using the UK population tariff
(Dolan et al., 1995). Total quality-adjusted life years (QALYs)were
calculated for each mother and child, using the area under the
curve approachafter linear interpolationbetween the timepoints.
Mother–child dyad QALYs were obtained by additively combining
individual mother and child QALYs (Weinstein et al., 2009).
A broad, societal perspective (including parental productivity
and school impacts) was adopted in assessing resource use and
costs. In addition to the intervention costs (captured through
therapists’ logs completed at each therapy session), values were
attached for measured school absence, time off work, and lost
leisure time (for mothers), use of non-NHS services (e.g. educa-
tional services) and personal costs of medications, all of which
was captured through parent diaries. An NHS perspective was
also adopted as per NICE guidance (NICE, 2013).
Treatment
Child Cognitive Behaviour Therapy (CCBT). All
children received eight-weekly one-hour sessions of individual
CBT. Treatment was delivered by one of seven qualified clinical
psychologists or cognitive behaviour therapists, following a
manual based on the ‘Cool Kids’ (Lyneham, Abbott, Wignall, &
Rapee, 2003) and ‘Coping Cat’ (Kendall & Hedtke, 2006)
programmes (both of which have established efficacy; Hudson
et al., 2009; Walkup et al., 2008). While these manuals
include more than eight treatment sessions, there is evidence
of good outcomes from similar CBT content for child anxiety
disorders delivered in eight hours or less (e.g. Gallagher,
Rabian, & McCloskey, 2004; Ginsburg & Drake, 2002). CCBT
was supervised by a highly experienced, clinical psychologist
and accredited cognitive behaviour therapist. Treatment
focused on helping children to identify and challenge negative
thinking styles, gradually increasing exposure to feared stimuli
and developing problem-solving skills. Mothers were included
at the beginning and end of each session to share progress and
feedback. As described in Appendix S3, CCBT treatment
adherence was equivalent across treatment arms.
CBT for maternal anxiety disorder (MCBT). MCBT
consisted of eight one-hour weekly sessions delivered by one of
five qualified clinical psychologists or cognitive behaviour
therapists (all supervised by a highly experienced, clinical
psychologist and accredited cognitive behaviour therapist) over
8 weeks. Given that mothers presented with a range of anxiety
disorders and given evidence for the efficacy of transdiagnostic
CBT treatments for anxiety disorders (Newby, McKinnon,
Kuyken, Gilbody, & Dalgleish, 2015), we followed a manu-
alised transdiagnostic treatment for adult disorders which
aimed to reverse the putative cognitive behavioural maintain-
ing mechanisms identified through individual formulation This
manual has not previously been systematically evaluated;
however, promising results were obtained in a case series
evaluation (McManus, Clark, Muse, & Shafran, 2015).
In the treatment arms that did not involve MCBT, mothers
received nondirective counselling (NDC), a supportive individ-
ual intervention that was not focussed specifically on reducing
symptoms of anxiety. NDC was provided by one of four
qualified counsellors (supervised by a highly experienced
counsellor/psychotherapist) following the manual of Borkovec
and Costello (1993). As shown in Appendix S3, the MCBT and
NDC were clearly distinct. MCBT and NDC were delivered first,
before the delivery of CCBT (see Table 1).
Mother–Child Interaction treatment (MCI). The MCI
intervention consisted of 10 sessions delivered over 8 weeks by
one of five qualified clinical psychologists or cognitive behaviour
therapists (supervised by an experienced clinical psychologist):
eight sessionswere with themother alone and twowere with the
mother and child together. This was a novel intervention
designed to target potentially anxiogenic features of the
mother–child relationship. Specifically, it aimed to enhance
maternalautonomypromotingcognitions (suchasconfidence in
the child’s ability to face challenge) and behaviours, and reduce
potentially anxiogenic behaviours. This was achieved through a
combination of specific strategies from existing family interven-
tions for childhood anxiety (Lyneham et al., 2003) with the
addition of video-feedback techniques developed and piloted by
the trial investigators. The two joint mother and child sessions
involved the mother and child completing structured tasks that
were video-recorded for reference in later sessions.
To balance therapist contact, sessions that focused on the
promotion of a healthy lifestyle (Healthy Living Control, HLC)
were delivered in the treatment arms that did not receive the
MCI intervention. This intervention was principally concerned
with family diet and exercise based on existing interventions
applied within school settings (BDA, 2003) and was delivered
by one of eight therapists (under supervision of an experienced
clinical psychologist). MCI/HLC was delivered in parallel with
CCBT. As shown in Appendix S3, MCI and HLC were clearly
distinct.
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Analysis
A comprehensive statistical analysis plan was prepared before
embarking on the analysis (Appendix S4).
In line with our hypotheses and power analysis, we set out to
make two sets of pairwise comparisons (MCBT+CCBT vs.
CCBT+Con; and MCI+CCBT vs. CCBT+Con). Dichotomous
outcome variables (e.g. diagnostic outcomes) were analysed
using a modified Poisson regression approach with robust
error variance adjusting for the minimisation factors [child age,
child gender, type of child anxiety disorder (GAD, social
phobia, SAD, other), baseline severity of the child’s and the
mother’s primary anxiety disorder (ADIS Clinician Severity
Rating)]. This approach allows for adjusted relative risks to be
presented (Zou, 2004). All analyses are presented based on the
intention-to-treat (ITT) population. Sensitivity analyses of the
primary endpoints included: (a) no adjustment for minimisa-
tion criteria, (b) per-protocol population (i.e. those participants
who had received at least half of the treatment sessions and
had data for the post-treatment assessments) and (c) multiple
imputation analysis (see Appendix S2). Primary outcome
results did not change based on the prespecified sensitivity
analyses, nor when best- and worst-case scenarios were used
in the context of the multiple imputation analysis. Continuous
outcomes were modelled using linear regression, adjusted for
baseline scores and minimisation factors. No adjustments
were made to the confidence intervals or p-values to account
for multiplicity.
Current best-practice methods were adhered to for conduct-
ing and reporting economic evaluations alongside trials
(Drummond, Sculpher, Claxton, Stoddart, & Torrance, 2015;
Husereau et al., 2013; NICE, 2013; Petrou & Gray, 2011). A
broad societal perspective cost-utility analysis framework was
adopted for the base case to assess the cost-effectiveness of (a)
CCBT+MCBT compared to CCBT; and (b) CCBT+MCI compared
with CCBT. Costs of the nonspecific treatments (NDC/HLC)
were excluded in the base-case analyses. This was in recogni-
tion of the fact that the main aim of any economic evaluation is
to estimate the likely cost-effectiveness of a change in clinical
practice in real-world settings, rather than in ideal controlled
conditions (as in efficacy trials). Those costs were instead
included in some of the sensitivity analyses. Costs were
expressed in pounds sterling (£) at 2011/2012 prices. Given
the short time-frame of the trial and follow-up, discounting
was not applied to costs or effects. The base-case analyses
were performed on an ITT basis. Mean imputation methods
were used for missing resource use and health outcomes
deemed highly deterministic (e.g. face-to-face therapists con-
tact), and multiple imputation for other resources (e.g. use of
medications), under the assumption of missing at random
(Faria, Gomes, Epstein, & White, 2014). For each mother and
child participant, all components of treatment costs, stratified
by category of resource use and other broader societal costs
(educational services, travel costs, time off school/work) were
calculated by multiplying units of resource use by their unit
costs (see Table S2). These values were then summed to obtain
a total cost for each child/mother. Effects were identified and
measured using child/mother QALYs, derived from the EQ-
5D-Y and EQ-5D-3L child and mother report, respectively.
Incremental mean costs and effects, and the associated 95%
CIs, were estimated comparing the two intervention groups for
each of the two comparisons (CCBT+MCBT vs. CCBT; and
CCBT+MCI vs. CCBT). Incremental cost-effectiveness ratios
(ICERs) were estimated and reported where relevant. Uncer-
tainty in the cost-effectiveness results was analysed using
cost-effectiveness acceptability curves (CEACs) over a range of
potential threshold values that the health system and the
wider society might be willing to pay for an additional QALY
gained (Fenwick, Marshall, Levy, & Nichol, 2006). Extensive
sensitivity analyses were performed for each of the two base-
case comparisons (CCBT+MCBT vs. CCBT; and CCBT+MCI vs.
CCBT) and are detailed in Table S3. All analyses were
conducted using Stata Software: Release 12, StataCorp 2011.
Results
Baseline characteristics were well balanced across
treatment arms (see Table 2). Numbers of available
participants for each treatment arm are shown in
Figure 1. No important harms due to any of the
interventions or trial procedures were reported dur-
ing the trial.
Manipulation checks
We first examined the extent to which delivery of the
adjunct treatments was associated with change in
the putative maintenance mechanisms that were
targeted; maternal anxiety disorder status and
change in maternal cognitions and behaviours.
MCBT was successful in changing maternal anxiety
disorder status. At Assessment 1B (i.e. after com-
pleting MCBT), 58.5% (n = 38) of mothers in the
MCBT arm had recovered from their primary diag-
nosis compared to 36.5% (n = 23) in the CCBT+Con
arm (who received NDC) (adj RR: 1.63 (95% CI: 1.13,
2.36), p = .009). The recovery rate in the MCI arm
was not different from that in the CCBT+Con arm
(who both received NDC) (adj RR: 1.22 (95% CI: 0.83,
1.81), p = .31).
At assessment 2 (i.e. after the children had
received CCBT), many of the mothers in the
CCBT+Con arm had recovered from their primary
disorder and there was, therefore, no longer a
superiority in this respect for the CCBT+MCBT arm
(CCBT+MCBT- CCBT+Con adj RR: 1.23 (95% CI:
0.90–1.68, p = .21; CCBT+MCI- CCBT+Con adj RR:
1.27 (95% CI: 0.93–1.74, p = .13).
Change in observed overprotection (across all
three mother–child tasks) at the end of all treatment
(Assessment 2) was greater in the CCBT+MCI arm
compared to CCBT+Con (adjusted mean difference in
change from baseline, (0.03 (0.06, 0.004),
p = .03). There was no difference in change in
observed overprotection between the CCBT+MCBT
and CCBT+Con arms (0.02 (0.05, 0.009),
p = .17). There were no significant differences
between CCBT+Con and either CCBT+MCBT or
CCBT+MCI in terms of change in observed intrusive-
ness, positive behaviours or maternal expressed
anxiety (See Table S4 and S5).
Differences between the CCBT+Con and
CCBT+MCI arms were also found on change in
measures of maternal expectations of how scared
the child would be (0.67 (1.26, 0.07); p = .03)
and how in control the child would feel (0.53 (0.01,
1.05); p = .05), with mothers in the CCBT+MCI arm
predicting that their child would be less scared and
more in control. While a similar pattern was found,
the corresponding differences between the
CCBT+Con and CCBT+MCBT arms did not quite
© 2019 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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reach the conventional level of statistical signifi-
cance (Scared: 0.53 (1.12, 0.07), p = .08; Con-
trol: 0.50 (0.03, 1.02), p = .06). A summary of the
results of statistical analyses for maternal anxiety,
behaviours and cognitions is given in Table S5.
Child outcomes
Recovery from anxiety diagnoses. Rates of recov-
ery from the primary diagnosis and all anxiety
diagnoses are shown in Table 3, and statistical
analyses are summarised in Table 4. There were no
significant differences between either the CCBT+Con
and the CCBT+MCBT (adj RR: 1.22 (95% CI: 0.88,
1.67), p = .23) or the CCBT+MCI arm (adj RR: 1.21
(95% CI: 0.88, 1.65), p = .24) on the primary out-
come, that is recovery from primary anxiety disorder
at the post-treatment assessment (Assessment 2).
Similarly, there were no significant post-treatment
differences on recovery from all anxiety disorders
between the CCBT+Con and the CCBT+MCBT (1.06
(95% CI: 0.63, 1.78), p = .82) or CCBT+MCI arms
(adj RR: 1.48 (95% CI: 0.92, 2.37). At six months
post-treatment (Assessment 3), again there was no
difference between the CCBT+Con arm and either
the CCBT+MCBT (Free of primary adj RR 1.09 (95%
CI: 0.81, 1.46), p = .57; Free of all adj RR 1.04 (95%
CI: 0.70, 1.53), p = .86) or the CCBT+MCI arm [Free
of primary adj RR: 1.26 (95% CI: 0.97, 1.64), p = .08;
Free of all adj RR: 1.04 (95% CI: 0.71, 1.55)].
Similarly, at 12 months post-treatment, there was
no difference between the CCBT+Con arm and either
the CCBT+MCBT (Free of primary adj RR: 0.85 (95%
CI: 0.65, 1.12), p = .26; Free of all adj RR: 0.89 (95%
CI: 0.61, 1.31), p = .57) or the CCBT+MCI arm (Free
of primary adj RR: 1.04 (95% CI: 0.82, 1.30), p = .77;
Free of all adj RR: 1.01 (95% CI: 0.70, 1.45), p = .97).
Clinical Global Impressions of Improvement (CGI-
I). As shown in Table 4, at the post-treatment
assessment (Assessment 2), there were no signifi-
cant differences between the groups in terms of rates
of ‘much’ or ‘very much’ improvement (CCBT+MCBT
vs. CCBT+Con adj RR: 1.25 (95% CI: 0.99, 1.57),
p = .06; CCBT+MCI vs. CCBT+Con adj RR: 1.18
(95% CI: 0.93, 1.50), p = .17). Differences were even
smaller at the six month (Assessment 3)
(CCBT+MCBT vs. CCBT+Con adj RR: 0.97 (95% CI:
0.79, 1.19), p = .77; CCBT+MCI vs. CCBT+Con adj
RR: 1.16 (95% CI: 0.94, 1.33), p = .22) and
12 months post-treatment assessment (Assessment
4; CCBT+MCBT vs. CCBT+Con adj RR: 1.02 (95% CI:
0.82, 1.27), p = .83; CCBT+Con vs. CCBT+MCI adj
RR: 1.05 (95% CI: 0.85, 1.30), p = .63).
Economic evaluation
Missing resource use data were prevalent (Table S6).
Mother and child combined HRQoL results are
presented in Table S7 (unadjusted differences) and
Tables S8 and S9 (differences adjusted for child’s
and mother’s baseline utilities). At 12 months, in the
Table 2 Baseline characteristics by treatment arm
CCBT+Con N = 71 CCBT+MCBT N = 69 CCBT+MCI N = 71
Child age (mean, SD) 10.28 (1.49) 10.29 (1.56) 10.10 (1.68)
Ethnicity n (%) White British 67 (94.37) 58 (84.06) 55 (77.46)
Sex n (%) Male 34 (47.89) 35 (50.72) 32 (45.07)
Parent marital status n (%) married/living with partner 39 (54.93) 50 (72.46) 46 (64.79)
Family socioeconomic statusn (%) ‘higher’/‘professional’ 29 (40.85) 39 (56.52) 38 (53.52)
Child: ADIS-c/p primary anxiety disorder
Separation anxiety disorder n (%) 19 (26.76) 16 (23.19) 21 (29.58)
Social anxiety disorder n (%) 16 (22.54) 18 (26.09) 14 (19.72)
Generalised anxiety disorder n (%) 22 (31.00) 20 (28.96) 24 (33.80)
Specific phobiaa n (%) 8 (11.27) 11 (15.94) 5 (7.04)
Panic disorder  Agoraphobia n (%) 4 (5.63) 2 (2.90) 4 (5.63)
Selective mutisma n (%) 0 0 1 (1.41)
Anxiety disorder not otherwise specified n (%) 2 (2.82) 2 (2.90) 2 (2.82)
ADIS-c/p primary diagnosis severity (CSR)Mean (SD) 5.65 (0.80) 5.71 (0.79) 5.69 (0.79)
Mother: ADIS primary disorder
Social anxiety disorder n (%) 9 (12.70) 14 (20.3) 11 (15.49)
Generalised anxiety disorder n (%) 37 (52.10) 35 (50.7) 40 (56.34)
Specific phobiaa n (%) 12 (16.90) 17 (24.64) 9 (12.68)
Panic disorder  Agoraphobia n (%) 3 (4.2) 1 (1.4) 3 (4.23)
Other (ADNOS, hypochondriasis, PTSD, OCD) 5 (7.04) 2 (2.9) 8 (11.27)
MDDb n (%) 5 (7) 0 0
ADIS primary diagnosis severity (CSR)Mean (SD) 5.24 (1.01) 5.17 (0.89) 5.31 (0.98)
ADNOS, anxiety disorder not otherwise specified; CCBT+Con, child cognitive behaviour therapy + nonspecific control interventions;
CSR, clinical severity rating; MCBT, CCBT + maternal cognitive behaviour therapy; MCI, CCBT + mother–child interaction
treatment; MDD, major depressive disorder; OCD, obsessive-compulsive disorder; PTSD, post-traumatic stress disorder.
aChildren with specific phobia and selective mutism were only included if also met diagnostic criteria for another comorbid anxiety
disorder.
bThese mothers had a current anxiety disorder but MDD had the highest severity.
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base-case analysis, the CCBT+Con arm conferred
slightly higher QALYs than the CCBT+MCBT arm
(CCBT+MCBT vs. CCBT+Con: 0.04 (95% CI: 0.12,
0.04), p = .29), whilst the CCBT+MCI arm conferred
slightly higher QALYs than the CCBT+Con arm
(CCBT+MCI vs. CCBT+Con: 0.02 (95% CI: 0.05,
0.09), p = .54). Neither of these differences was
statistically significant. Mean NHS and societal cost
differences for the two comparisons are reported in
Tables S10–S12. When a societal perspective was
adopted (base-case analysis; Table S11),
CCBT+MCBT was £482 more costly than CCBT
(95% CI: £827, £1,791); this was not significant
(p = .47). However, from an NHS perspective, costs
for CCBT+MCBT were £797 significantly greater than
CCBT (95% CI: £603, £991; p < .001). For
CCBT+MCI, when a societal perspective was adopted
[base-case analysis; Table S10), CCBT+MCI was
£154 more costly than CCBT (95% CI: £1,239,
£1,547)], again an insignificant difference (p = .83).
The NHS perspective costs for CCBT+MCI, on the
other hand, were £808 greater than for CCBT (95%
CI: £610, £1,006), a statistically significant differ-
ence (p < .001).
Key cost drivers in both of these base-case com-
parisons were the differential treatment delivery
costs in both the CCBT+MBCT and CCBT+MCI arms
compared with CCBT only (Tables S11 and S12).
While the CCBT+Con arm had higher absences from
school and work costs than the other two arms, few
differences were statistically significant although,
notably, the lower costs of mother’s lost days of work
in the CCBT+MCI arm than in the CCBT+Con arm
were significant (Table S12).
Taking sampling uncertainty into consideration,
the cost-effectiveness acceptability curves (CEACs)
for the two base-case analyses showed that, in view
of the joint distribution of incremental mean costs
and effects, the CCBT+MBCT arm was not likely to
be a cost-effective alternative to CCBT (Figure 2,
Panel 1, and Table S8, base-case line). The
probability that the CCBT+MCI arm was cost-effec-
tive compared to CCBT (Figure 2, Panel 2, and
Table S9 base-case line) was between 60% and
64% based on UK National Institute for Health and
Care Excellence thresholds for accepted levels of
willingness to pay for an additional QALY (usually
between £20,000 and £30,000). Sensitivity analyses
reinforced the findings of the base-case analyses,
with the CCBT+MCBT arm not being cost-effective
compared with the CCBT arm across the majority of
sensitivity analyses (Table S8) [other than the sce-
nario where the CCBT+MCBT arm was less costly
but also less effective (SA 4 and SA 10)]. For the
comparison between the CCBT+MCI arm and CCBT
(Table S9), the CCBT+MCI arm may be a cost-
effective alternative to CCBT from a societal perspec-
tive (insignificantly higher costs or less costly,
insignificantly higher QALYs), as reflected by the
probability of cost-effectiveness being greater than
60% overall.
Discussion
Good outcomes were achieved for both children and
their mothers across all treatment arms but neither
adding treatment of maternal anxiety (MCBT) nor
treatment of the mother–child relationship (MCI) to
individual child-focused CBT conferred a significant
benefit to children with anxiety disorders whose
mothers also had a current anxiety disorder.
Although adding both adjunct treatments achieved
higher child recovery rates post-treatment than the
CCBT plus control treatment arm (where neither
maternal anxiety nor potentially anxiogenic parent-
ing received specific therapeutic attention), the
advantages were not statistically significant. How-
ever, from a broad societal perspective combining
mother/child QALYs and costs, including productiv-
ity and school impacts, the economic evaluation
indicated that CCBT+MCI arm (but not the
CCBT+MCBT arm) may be cost-effective compared
Table 3 Primary and secondary categorical (child) outcomes
Initial
assessment (1)
Post-treatment
assessment (2)
6-month post-treatment
assessment (3)
12-month post-treatment
assessment (4)
n (%) free of primary diagnosis
CCBT+ Con 0 27 (48.21) 29 (59.18) 31 (72.09)
CCBT+MCBT 0 35 (58.33) 34 (64.15) 30 (60.00)
CCBT+MCI 0 37 (59.68) 38 (74.51) 34 (73.91)
n (%) free of all anxiety diagnoses
CCBT_+Con 0 16 (28.57) 23 (46.94) 23 (53.49)
CCBT+MCBT 0 18 (30.00) 25 (47.17) 23 (46.00)
CCBT+MCI 0 25 (40.32) 24 (47.06) 24 (52.17)
n (%) CGI-I ‘much’/’very much’ improved
CCBT +Con 0 36 (64.29) 39 (79.59) 33 (76.74)
CCBT+MCBT 0 48 (80.00) 41 (77.36) 39 (78.00)
CCBT+MCI 0 47 (75.81) 45 (88.24) 37 (80.43)
See Table S1 for descriptive statistics for secondary continuous outcomes.
CCBT+Con, child cognitive behaviour therapy + nonspecific control interventions; CCBT+MCBT, CCBT + maternal cognitive
behaviour therapy; CCBT+MCI, CCBT + mother–child interaction treatment; CGI-I Clinical Global Impression – Improvement.
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to CCBT. Notably, the probability of the CCBT+MCI
arm being cost-effective lessened when a more
restricted NHS perspective was adopted and the
gains from reduced school absenteeism and moth-
ers’ productivity/employment excluded. This indi-
cates that costs associated with childhood anxiety
disorders are likely to be underestimated if a purely
healthcare provider perspective is adopted, and it
affirms the importance of including wider family/
society born costs and outcomes in mental health
economic evaluations (Creswell et al., 2017; Tilford
et al., 2015; Tubeuf & Guthmuller, 2017).
Despite these potential broader economic benefits,
it is important to consider the lack of significant
clinical effects of the two active adjunct interventions
(MCI/MCBT). The study was powered to detect a 30%
difference in the proportion of recovered children,
based on a projected recovery rate from child CBT of
40% (Cobham et al., 1998). While a 30% difference in
recovery between CBT plus the adjunct treatments
and CBT plus the control interventions might be
considered conservative (as smaller differences may
still be clinically meaningful), an anticipated success
rate of 40% from individual CBT could have been
considered optimistic, given findings from a more
recent trial – the first to examine treatment of child
anxiety disorder in the context of diagnosed parental
anxiety disorder – where a recovery rate of only 33%
was found (Hudson et al., 2014). However, the CCBT
plus control treatment arm in the current study
performed considerably better than expected, with
48% of children being free of their primary anxiety
disorder and 64% ‘much’ or ‘very much’ improved
immediately post-treatment, and over 70% free of
their primary diagnosis and ‘much/very much
improved’ a year after treatment. Indeed, these suc-
cess rates are similar to those found from more
intensive (14 session) CCBT for children with anxiety
disorders, regardless of parental anxiety disorder
status, where the proportions ‘much’/’very much’
improved were 60% at post-treatment (Walkup et al.,
2008) and 72% at six-month follow-up (Piacentini
et al., 2014), respectively. The unexpectedly high rate
of recovery within the CCBT plus control arm in the
current study is unlikely to be a function of particular
features of our sample, as our study population was
comparable to other clinic samples in the literature.
There could, however, havebeenanaddedvalue of the
nonspecific interventions, all of which provided some
level of parental support. This raises the possibility
that the modest outcomes typically found for anxious
children in the context of parental anxietydisorder are
in fact a result of other associated factors – for
example, other stressors experienced by the family
(see, e.g. Schleider et al., 2015) – which might have
been addressed to some extent in this trial by the
generic support received by all mothers.
Given the novelty of the adjunctive treatments, the
degree to which they were successful in altering their
respective targets also needs to be considered. In the
one previous study that assessed the impact of
adding CBT for parental anxiety disorders to CBT
for child anxiety disorders (Hudson et al., 2014), the
failure to find significant differences in child out-
comes may have been attributable to the parental
CBT not reducing parental anxiety. In the current
study, however, compared to nondirective coun-
selling, MCBT was associated with a significant
Table 4 Statistical analyses for child primary and secondary
categorical outcomes
Parameter Adjusted RR 95% CI
p-
value
Free from primary diagnosis at post-treatment assessment (2)
Treatment CCBT+Con Ref.
CCBT+MCBT 1.18 0.83–1.62 .285
CCBT+MCI 1.22 0.90–1.67 .203
Free from primary diagnosis at 6-month post-treatment
assessment (3)
Treatment CCBT+Con Ref.
CCBT+MCBT 1.09 0.81–1.46 .566
CCBT+MCI 1.26 0.97–1.64 .077
Free from primary diagnosis at 12-month post-treatment
assessment (4)
Treatment CCBT+Con Ref.
CCBT+MCBT 0.85 0.65–1.12 .257
CCBT+MCI 1.04 0.82–1.30 .766
Free from all anxiety diagnoses at post-treatment assessment
(2)
Treatment CCBT+Con Ref.
CCBT+MCBT 1.06 0.63–1.78 .816
CCBT+MCI 1.48 0.92–2.37 .102
Free from all anxiety diagnoses at 6-month post-treatment
assessment (3)
Treatment CCBT+Con Ref.
CCBT+MCBT 1.04 0.70–1.53 .860
CCBT+MCI 1.04 0.71–1.55 .814
Free from all anxiety diagnoses at 12-month post-treatment
assessment (4)
Treatment CCBT+Con Ref.
CCBT+MCBT 0.89 0.61–1.31 .569
CCBT+MCI 1.01 0.70–1.45 .972
CGI-I ‘much’/’very much’ improved at post-treatment
assessment (2)
Treatment CCBT+Con Ref.
CCBT+MCBT 1.26 1.00–1.59 .054
CCBT+MCI 1.20 0.95–1.53 .133
CGI-I ‘much’/’very much’ improved at 6-month post-treatment
assessment (3)
Treatment CCBT+Con Ref.
CCBT+MCBT 0.97 0.79–1.19 .771
CCBT+MCI 1.16 0.94–1.33 .216
CGI-I ‘much’/’very much’ improved at 12-month post-
treatment assessment (4)
Treatment CCBT+Con Ref.
CCBT+MCBT 1.02 0.82–1.27 .834
CCBT+MCI 1.05 0.85–1.30 .628
Adjusted for child age, child gender, type of child anxiety
disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and
baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
CCBT+Con, child cognitive behaviour therapy + nonspecific
control interventions; CCBT+MCBT, CCBT + maternal cogni-
tive behaviour therapy; CCBT+MCI, CCBT + mother–child
interaction treatment; CGI-I, Clinical Global Impression –
Improvement; Ref., reference category.
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Table 5 Statistical analyses for child secondary continuous outcomes
Treatment
arm N
Adjusteda Mean change
(95% CI)
Adjusteda Mean difference
(95% CI)
p
value
Anxiety symptoms (SCAS-c) – mid-
treatment assessment (1B)
CCBT+Con 53 7.71 (10.87, 4.56) Ref
CCBT+MCBT 60 6.15 (9.13, 3.17) 1.57 (2.82, 5.96) .482
CCBT+MCI 64 6.02 (8.89, 3.15) 1.69 (2.61, 5.99) .438
Anxiety symptoms (SCAS-c) – post-
treatment assessment (2)
CCBT+Con 45 19.68 (23.48, 15.89) Ref
CCBT+MCBT 46 13.71 (17.49, 9.92) 5.97 (0.54, 11.41) .031
CCBT+MCI 52 15.73 (19.27, 12.19) 3.96 (1.28, 9.19) .137
Anxiety symptoms (SCAS-c) – 6-month
post-treatment assessment (3)
CCBT+Con 41 17.85 (22.73, 12.98) Ref
CCBT+MCBT 43 16.59 (21.35, 11.83) 1.26 (5.56, 8.08) .715
CCBT+MCI 41 17.60 (22.52, 12.67) 0.26 (6.77, 7.28) .943
Anxiety symptoms (SCAS-c) – 12-month
post-treatment assessment (4)
CCBT+Con 31 18.11 (23.18, 13.03) Ref
CCBT+MCBT 34 18.92 (23.82, 14.01) 0.81 (7.96, 6.34) .823
CCBT+MCI 37 17.98 (22.59, 13.38) 0.12 (6.73, 6.97) .972
Anxiety symptoms (SCAS-p) – mid-
treatment assessment (1B)
CCBT+Con 42 8.30 (11.68, 4.93) Ref
CCBT+MCBT 44 8.14 (11.45, 4.83) 0.17 (4.62, 4.96) .944
CCBT+MCI 48 9.38 (12.54, 6.21) 1.07 (5.75, 3.62) .653
Anxiety symptoms (SCAS-p) – post-
treatment assessment (2)
CCBT+Con 36 18.00 (21.09, 14.88) Ref
CCBT+MCBT 39 16.77 (19.75, 13.78) 1.22 (3.15, 5.59) .581
CCBT+MCI 38 18.30 (21.35, 15.25) 0.32 (4.77, 4.14) .888
Anxiety symptoms (SCAS-p) – 6-month
post-treatment assessment (3)
CCBT+Con 36 17.44 (21.03, 13.84) Ref
CCBT+MCBT 41 16.62 (20.00, 13.25) 0.82 (4.11, 5.74) .743
CCBT+MCI 38 19.17 (22.72, 15.61) 1.73 (6.86, 3.40) .505
Anxiety symptoms (SCAS-p) – 12-month
post-treatment assessment (4)
CCBT+Con 30 22.37 (26.62, 18.12) Ref
CCBT+MCBT 31 16.36 (20.58, 12.15) 6.01 (0.01, 12.02) .050
CCBT+MCI 33 20.74 (24.78, 16.71) 1.62 (4.27, 7.51) .585
Anxiety symptoms (SCAS-t) – post-
treatment assessment (2)
CCBT+Con 7 4.02 (11.27, 3.23) Ref
CCBT+MCBT 14 4.94 (9.90, 0.03) 0.92 (10.69, 8.85) .847
CCBT+MCI 12 5.31 (10.53, 0.10) 1.29 (10.86, 8.27) .782
Anxiety symptoms (SCAS-t) – 6-month
post-treatment assessment (3)
CCBT+Con 4 1.88 (15.75, 12.00) Ref
CCBT+MCBT 9 15.07 (22.85, 7.29) 13.19 (30.33, 3.94) .123
CCBT+MCI 15 10.26 (15.89, 4.64) 8.39 (24.79, 8.01) .296
Anxiety symptoms (SCAS-t) – 12-month
post-treatment assessment (4)
CCBT+Con 4 7.90 (17.17, 1.37) Ref
CCBT+MCBT 4 0.04 (18.30, 18.22) 7.86 (12.83, 28.55) .244
CCBT+MCI 5 11.90 (23.14, 0.66) 4.00 (18.25, 10.25) .351
Child Anxiety Impact Scale (CAIS-c) –
mid-treatment assessment (1B)
CCBT+Con 52 4.30 (7.36, 1.24) Ref
CCBT+MCBT 58 6.48 (9.41, 3.55) 2.18 (6.51, 2.15) .322
CCBT+MCI 62 7.19 (9.97, 4.41) 2.89 (7.03, 1.26) .171
Child Anxiety Impact Scale (CAIS-c) –
post-treatment assessment (2)
CCBT+Con 44 8.19 (12.10, 4.28) Ref
CCBT+MCBT 45 6.28 (10.20, 2.37) 1.91 (3.73, 7.55) .505
CCBT+MCI 53 6.49 (10.05, 2.93) 1.70 (3.63, 7.03) .530
Child Anxiety Impact Scale (CAIS-c) – 6-
month post-treatment assessment (3)
CCBT+Con 38 12.45 (15.06, 9.84) Ref
CCBT+MCBT 43 11.02 (13.50, 8.54) 1.43 (2.21, 5.07) .437
CCBT+MCI 41 10.75 (13.29, 8.21) 1.70 (1.97, 5.37) .361
Child Anxiety Impact Scale (CAIS-c) –
12-month post-treatment assessment
(4)
CCBT+Con 29 12.83 (17.14, 8.51) Ref
CCBT+MCBT 33 9.25 (13.41, 5.09) 3.57 (2.59, 9.74) .253
CCBT+MCI 37 11.71 (15.48, 7.93) 1.12 (4.59, 6.83) .698
Child Anxiety Impact Scale (CAIS-p) –
mid-treatment assessment (1B)
CCBT+Con 39 2.39 (4.69, 0.08) Ref
CCBT+MCBT 39 5.57 (7.89, 3.25) 3.18 (6.51, 0.15) .061
CCBT+MCI 40 4.77 (7.05, 2.48) 2.38 (5.67, 0.91) .154
Child Anxiety Impact Scale (CAIS-p) –
post-treatment assessment (2)
CCBT+Con 33 10.19 (12.37, 8.01) Ref
CCBT+MCBT 35 12.95 (15.09, 10.80) 2.76 (5.86, 0.34) .080
CCBT+MCI 31 10.15 (12.45, 7.84) 0.04 (3.20, 3.28) .980
Child Anxiety Impact Scale (CAIS-p) – 6-
month post-treatment assessment (3)
CCBT+Con 35 9.25 (12.12, 6.37) Ref
CCBT+MCBT 37 12.13 (14.95, 9.31) 2.88 (6.92, 1.16) .160
CCBT+MCI 34 9.69 (12.68, 6.70) 0.44 (4.61, 3.73) .835
Child Anxiety Impact Scale (CAIS-p) –
12-month post-treatment assessment
(4)
CCBT+Con 28 9.50 (12.44, 6.56) Ref
CCBT+MCBT 27 12.11 (15.19, 9.04) 2.61 (6.88, 1.66) .227
CCBT+MCI 31 12.15 (14.99, 9.32) 2.65 (6.72, 1.42) .199
Depression symptoms (SMFQ-c) – mid-
treatment assessment (1B)
CCBT+Con 52 2.83 (3.96, 1.70) Ref
CCBT+MCBT 60 2.09 (3.15, 1.03) 0.74 (0.82, 2.30) .350
CCBT+MCI 64 2.48 (3.50, 1.45) 0.36 (1.18, 1.90) .649
Depression symptoms (SMFQ-c) – post-
treatment assessment (2)
CCBT+Con 46 5.03 (6.35, 3.71) Ref
CCBT+MCBT 47 2.25 (3.57, 0.93) 2.78 (0.88, 4.68) .004
CCBT+MCI 54 2.70 (3.92, 1.48) 2.33 (0.52, 4.14) .012
Depression symptoms (SMFQ-c) – 6-
month post-treatment assessment (3)
CCBT+Con 40 3.81 (5.33, 2.29) Ref
CCBT+MCBT 44 3.52 (4.97, 2.06) 0.30 (1.82, 2.42) .783
CCBT+MCI 39 3.97 (5.52, 2.41) 0.16 (2.36, 2.04) .887
(continued)
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Table 5 (continued)
Treatment
arm N
Adjusteda Mean change
(95% CI)
Adjusteda Mean difference
(95% CI)
p
value
Depression symptoms (SMFQ-c) – 12-
month post-treatment assessment (4)
CCBT+Con 28 4.08 (5.95, 2.21) Ref
CCBT+MCBT 35 4.20 (5.91, 2.49) 0.12 (2.71, 2.48) .928
CCBT+MCI 37 2.09 (3.72, 0.47) 1.99 (0.48, 4.46) .113
Depression symptoms (SMFQ-p) – mid-
treatment assessment (1B)
CCBT+Con 40 1.32 (2.97, 0.32) Ref
CCBT+MCBT 38 3.17 (4.86, 1.47) 1.85 (4.24, 0.55) .130
CCBT+MCI 44 0.63 (2.20, 0.94) 0.69 (1.61, 3.00) .552
Depression symptoms (SMFQ-p) – post-
treatment assessment (2)
CCBT+Con 34 4.60 (6.03, 3.18) Ref
CCBT+MCBT 38 5.66 (7.03, 4.29) 1.06 (3.07, 0.96) .301
CCBT+MCI 35 5.64 (7.07, 4.22) 1.04 (3.08, 1.00) .314
Depression symptoms (SMFQ-p) – 6-
month post-treatment assessment (3)
CCBT+Con 36 4.25 (5.82, 2.67) Ref
CCBT+MCBT 38 5.86 (7.40, 4.32) 1.61 (3.83, 0.61) .154
CCBT+MCI 36 4.90 (6.49, 3.30) 0.65 (2.91, 1.61) .570
Depression symptoms (SMFQ-p) – 12-
month post-treatment assessment (4)
CCBT+Con 30 5.14 (6.81, 3.48) Ref
CCBT+MCBT 29 4.54 (6.25, 2.82) 0.61 (1.82, 3.04) .619
CCBT+MCI 33 5.97 (7.55, 4.39) 0.83 (3.11, 1.46) .474
Conduct problems (SDQ-c) – mid-
treatment assessment (1B)
CCBT+Con 54 0.48 (0.88, 0.08) Ref
CCBT+MCBT 58 0.18 (0.56, 0.21) 0.30 (0.26, 0.86) .289
CCBT+MCI 65 0.26 (0.62, 0.11) 0.22 (0.33, 0.77) .427
Conduct problems (SDQ-c) – post-
treatment assessment (2)
CCBT+Con 47 0.61 (1.08, 0.14) Ref
CCBT+MCBT 47 0.52 (1.00, 0.05) 0.09 (0.59, 0.76) .803
CCBT+MCI 55 0.50 (0.94, 0.07) 0.10 (0.54, 0.75) .748
Conduct problems (SDQ-c) – 6-month
post-treatment assessment (3)
CCBT+Con 42 0.88 (1.35, 0.42) Ref
CCBT+MCBT 44 0.91 (1.37, 0.46) 0.03 (0.68, 0.62) .925
CCBT+MCI 42 0.81 (1.28, 0.34) 0.07 (0.60, 0.74) .832
Conduct problems (SDQ-c) – 12-month
post-treatment assessment (4)
CCBT+Con 31 1.21 (1.87, 0.55) Ref
CCBT+MCBT 34 0.94 (1.58, 0.30) 0.27 (0.65, 1.18) .562
CCBT+MCI 38 1.00 (1.59, 0.40) 0.21 (0.68, 1.10) .637
Conduct problems (SDQ-p) – mid-
treatment assessment (1B)
CCBT+Con 42 0.14 (0.54, 0.26) Ref
CCBT+MCBT 46 0.18 (0.56, 0.21) 0.04 (0.60, 0.52) .897
CCBT+MCI 50 0.08 (0.45, 0.29) 0.06 (0.49, 0.61) .836
Conduct problems (SDQ-p) – post-
treatment assessment (2)
CCBT+Con 37 0.65 (1.06, 0.24) Ref
CCBT+MCBT 41 0.74 (1.12, 0.35) 0.09 (0.66, 0.49) .763
CCBT+MCI 40 0.84 (1.23, 0.45) 0.19 (0.77, 0.39) .515
Conduct problems (SDQ-p) – 6-month
post-treatment assessment (3)
CCBT+Con 39 0.47 (0.86, 0.09) Ref
CCBT+MCBT 42 0.99 (1.36, 0.62) 0.51 (1.05, 0.02) .060
CCBT+MCI 41 1.11 (1.49, 0.73) 0.64 (1.19, 0.09) .022
Conduct problems (SDQ-p) – 12-month
post-treatment assessment (4)
CCBT+Con 32 1.04 (1.56, 0.53) Ref
CCBT+MCBT 32 0.89 (1.40, 0.38) 0.16 (0.57, 0.89) .668
CCBT+MCI 38 0.85 (1.31, 0.38) 0.20 (0.50, 0.89) .575
Conduct problems (SDQ-t) – post-
treatment assessment (2)
CCBT+Con 18 0.35 (0.21, 0.91) Ref
CCBT+MCBT 22 0.17 (0.68, 0.35) 0.52 (1.30, 0.27) .190
CCBT+MCI 23 0.11 (0.62, 0.39) 0.46 (1.24, 0.31) .236
Conduct problems (SDQ-t) – 6-month
post-treatment assessment (3)
CCBT+Con 12 0.57 (0.36, 1.50) Ref
CCBT+MCBT 18 0.21 (0.98, 0.57) 0.78 (1.98, 0.42) .196
CCBT+MCI 22 0.31 (0.37, 1.00) 0.26 (1.42, 0.90) .654
Conduct problems (SDQ-t) – 12-month
post-treatment assessment (4)
CCBT+Con 9 0.09 (1.21, 1.03) Ref
CCBT+MCBT 11 0.27 (1.30, 0.75) 0.18 (1.71, 1.34) .805
CCBT+MCI 12 0.41 (0.54, 1.36) 0.50 (0.99, 2.00) .490
Child Adjustment to School (CAS-t) –
post-treatment assessment (2)
CCBT+Con 18 0.86 (2.32, 0.60) Ref
CCBT+MCBT 24 1.96 (3.22, 0.70) 1.10 (3.11, 0.90) .275
CCBT+MCI 25 1.26 (2.48, 0.04) 0.40 (2.37, 1.57) .684
Child Adjustment to School (CAS-t) – 6-
month post-treatment assessment (3)
CCBT+Con 11 1.43 (3.85, 0.99) Ref
CCBT+MCBT 17 2.92 (4.91, 0.94) 1.50 (4.65, 1.66) .343
CCBT+MCI 23 1.40 (3.02, 0.23) 0.03 (2.92, 2.98) .985
Child Adjustment to School (CAS-t) –
12-month post-treatment assessment
(4)
CCBT+Con 9 2.56 (4.76, 0.37) Ref
CCBT+MCBT 10 0.04 (2.23, 2.14) 2.52 (0.62, 5.66) .110
CCBT+MCI 12 0.40 (2.29, 1.48) 2.16 (0.77, 5.09) .139
CAIS-c/p, Child Anxiety Impact Scale child/parent report; CCBT+Con, child cognitive behaviour therapy + nonspecific control
interventions; CCBT+MCBT, CCBT + maternal cognitive behaviour therapy; CCBT+MCI, CCBT + mother–child interaction
treatment; SCAS-c/p, Spence Children’s Anxiety Scale – child/parent report; SDQ-p, Strengths and Difficulties Questionnaire –
parent report; SMFQ-c/p, Short Mood and Feelings Questionnaire – child/parent report.
aAdjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity (ADIS
Clinician Severity Rating) of the child’s primary anxiety disorder, baseline severity (ADIS Mother self-report) of the mother’s primary
anxiety disorder and baseline questionnaire score.
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reduction in the frequency of maternal anxiety
disorder. However, after the children had received
treatment, there was no longer a significant differ-
ence in maternal disorder status, with all treatment
arms showing relatively high rates of recovery from
maternal disorders. This is consistent with previous
findings indicating that reductions in child anxiety
are associated with reductions in parental anxiety
(Settipani et al., 2013).
We conducted observational assessments of par-
ental responses before and after treatment for child
anxiety disorders which provided evidence that, in
terms of a relative change in overprotective beha-
viours, the mother–child interaction treatment was
successful. The MCI intervention was also associ-
ated with change in maternal cognitions associated
with confidence in child coping (i.e. reduced predic-
tions regarding child fear and increased predictions
regarding child control). Despite these positive ben-
efits, no significant benefit to child outcome was
conferred. Possible reasons for this may be that the
changes were not of sufficient magnitude to be of
benefit, or, as noted above, that change in these
factors is not in fact critical to changing child
anxiety. Notably, there was no specific benefit for
the MCI intervention on measures of maternal
expressed anxiety, intrusiveness or positive beha-
viours. While it is possible that the intervention was
ineffective with respect to these dimensions, it may
well be that these parental behaviours changed
equally across groups in response to improvements
in child anxiety (Silverman, Kurtines, Jaccard, &
Pina, 2009). However, it may also reflect limitations
in the extent to which these laboratory-based obser-
vational tasks assess parenting dimensions as they
are expressed in the home.
The study had several notable strengths, including
the use of reliable, blind raters to make assessments
of child and maternal anxiety and maternal beha-
viours and cognitions before and after treatment, the
inclusion of nonspecific interventions to balance
therapist contact, a design which allowed for isolat-
ing the effects of specifically targeting maternal
anxiety and parenting responses, and the inclusion
of a broad societal perspective, prospectively
designed economic evaluation measuring and valu-
ing both mother and child costs and outcomes.
These strengths need to be considered in the light of
various limitations. Although we allowed for 20%
loss to follow-up, by the one year post-treatment,
assessment retention was down to 61% in the
CCBT+Con arm. Although there were no clear base-
line differences between completers and those who
dropped out, it is of concern that the greatest drop-
out occurred during the eight-session maternal
counselling phase which may not have been a
sufficiently acceptable treatment approach for some
families. Whether dropouts overrepresented those
with good or bad treatment outcomes cannot be
determined, although the sensitivity analyses that
were conducted gave a consistent pattern of results
which suggest that this was not the case. Other
limitations include the relatively restricted demo-
graphic characteristics of the participants, who were
predominantly of nonminority ethnicity and rela-
tively high socioeconomic status. We elected to focus
on middle childhood (7–12 years) as anxiety disor-
ders can be reliably diagnosed at this age, particular
parental behaviours have been observed in the
context of parent anxiety disorder at this age
(Creswell et al., 2013), and it is likely that the nature
of parental influences on child anxiety varies with
child age (Connell & Goodman, 2002; Maccoby,
1992). We also focused on intervening with mothers
as parental influences have also been shown to differ
according to parent gender (B€ogels & Perotti, 2011).
As a result, however, the findings cannot be gener-
alised to younger children, to adolescents or to
interventions with fathers or other caregivers. The
study also included children and mothers with a
Panel 1 – CCBT+MCBT vs CCBT+Con Panel 2 – CCBT+MCI vs CCBT+Con
Figure 2 Cost-effectiveness acceptability curves for the base-case analyses. CCBT+Con, child-focused cognitive behaviour therapy +
nonspecific control interventions; CCBT+ MCBT, CCBT + CBT to target maternal anxiety disorder; CCBT+MCI, CCBT + intervention to target
the mother–child interaction
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broad range of anxiety disorders, and further work
needs to be done which takes account of the precise
form of parental and child anxiety.
For the health economics analyses, data on
resource use and costs of additional health and
personal social services beyond the NHS treatment
costs were characterised by a high percentage of
missing data. However, the economic results were
confirmed by multiple sensitivity analyses, including
a variation that best approximated a complete-case
scenario. The base-case economic evaluations
excluded the costs of the two nonspecific interven-
tions (i.e. family healthy living and nondirective
counselling for mothers), which were introduced to
match for therapist time/contact across the trial
arms, and are not commonly delivered in ‘real-world’
settings. While the sensitivity analyses that were
conducted including those costs confirmed and rein-
forced the base-case results, it should be acknowl-
edged that the nonspecific interventionsmaynot have
beencompletelyneutral in their effect.However, in the
absence of a valid counterfactual, we are unable to
quantify that potential impact. Furthermore, this
study should be regarded as providing an indication
of the short-term likely cost-effectiveness of
CCBT+MCBT or CCBT+MCI compared to CCBT, with
further research required to determine cost-effective-
ness in the longer term. Finally, generalising these
economic findings to other populations and settings
(e.g. different healthcare systems) is challenging and,
with the added complexity associated with capturing
the broader societal impact as well as the combined
mother/child impacts, the cost-effectiveness results
are best interpreted with caution.
In sum, the current study showed that good
clinical outcomes can be achieved for children with
anxiety disorders in the context of maternal anxiety
disorder by providing high-quality individual child
CBT together with some parental support. However,
although offering CBT to mothers for their own
anxiety disorders gave an early boost to the timing
of maternal recovery, it did not lead to a significant
clinical benefit in terms of child anxiety treatment
outcome and (given the higher costs) was not cost-
effective. An adjunctive treatment to target parenting
responses had a nonsignificant positive effect on
child outcomes, which, despite the higher costs, may
be cost-effective. The findings also suggest that
reductions in child anxiety may have a positive effect
on maternal mental health.
Supporting information
Additional supporting information may be found online
in the Supporting Information section at the end of the
article:
Appendix S1. Study protocol.
Appendix S2. Statistical analysis plan.
Appendix S3. Adherence and fidelity.
Appendix S4. Multiple imputation approach.
Table S1. Scores at each time point on continuous
secondary outcome measures.
Table S2. Unit costs.
Table S3. Sensitivity analyses for base-case compar-
isons.
Table S4. Descriptive data: Maternal anxiety disorders,
behaviours and cognitions.
Table S5. Manipulation checks: Statistical analyses for
maternal anxiety disorders, behaviours and cognitions.
Table S6. Health Economic data completeness (per-
centage of missing data reported).
Table S7. Child and mother combined Quality Adjusted
Life Years (QALYs) gained – CCBT+MCBT versus
CCBT+Con; CCBT+MCI versus CCBT+Con.
Table S8. Cost utility analysis – CCBT+MCBT versus
CCBT(+Con).
Table S9. Cost utility analysis – CCBT+MCI versus
CCBT(+Con).
Table S10. Societal cost mean differences –
CCBT+MCBT versus CCBT; CCBT+ MCI versus CCBT
(+Con).
Table S11. Treatment resource use mean differences –
CCBT+MCBT versus CCBT+Con.
Table S12. Treatment resource use mean differences –
CCBT+MCI versus CCBT+Con.
Acknowledgements
This trial was supported by grants from the Medical
Research Council/National Institute of Health Research
Efficacy and Mechanism Evaluation program (09/800/
17), Berkshire Healthcare Foundation Trust and the
Thames Valley Comprehensive Local Research Network;
C.C.was supportedbyMRCClinicianScientist Fellowship
(G0601874).Trial registrationnumber: ISRCTN19762288
(doi.10.1186/ISRCTN19762288). The full trial report can
be found here: doi: 10.3310/hta19380
The authors thank the participating families, the
managers, administrators, therapists, assessors,
coders, clinical supervisors and the Trial Steering and
Data Management and Ethics Committee members
(Chairs: Professor Jonathan Hill & John Geddes). The
authors also thank Liz White for her support in
preparing the manuscript. This report presents inde-
pendent research managed by the National Institute for
Health Research (NIHR). The views and opinions
expressed by authors in this publication are those of
the authors and do not necessarily reflect those of the
NHS, the NIHR, MRC, CCF, NETSCC or the Department
of Health. The authors have declared that they have no
competing or potential conflicts of interest.
Correspondence
Cathy Creswell, Department of Experimental Psychol-
ogy, University of Oxford, Anna Watts Building, Rad-
cliffe Observatory Quarter, Woodstock Road, Oxford,
OX2 6HG, UK; Email: cathy.creswell@psych.ox.ac.uk
Peter J. Cooper, School of Psychology and Clinical
Language Sciences, University of Reading, Reading,
Berkshire, RG6 6AL, UK; Email: p.j.cooper@reading.
ac.uk
© 2019 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
Child and Adolescent Mental Health.
Child and maternal anxiety disorder 13
Key points
 Treatment outcomes for children with anxiety disorders are impaired in the context of concurrent parental
anxiety disorder but it is unclear how to improve outcomes.
 In this RCT for children with anxiety disorders whose mothers also had a current anxiety disorder, individual
child-focused CBT was supplemented with treatments to (a) improve maternal anxiety (MCBT) or (b) alter
maternal responses to her child when faced with challenge (MCI).
 The adjunct treatments were successful in improving maternal anxiety and responses; however, this did not
lead to a significant benefit in terms of child anxiety treatment outcome.
 Good child outcomes were achieved for children with anxiety disorders in the context of maternal anxiety
disorder by providing high-quality individual child CBT together with some parental support.
 Reductions in child anxiety may also have a positive effect on maternal mental health.
 MCI (but not MCBT) may be a cost-effective psychological approach for the treatment of child anxiety
problems in the context of maternal anxiety disorders.
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